Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2012

View Archived Issues

Quisinostat evaluated in phase II cutaneous T-cell lymphoma trial

Amicus and GSK report 6-month results from first phase III study of Fabry's disease monotherapy

Infectex begins phase IIb/III trial of SQ-109

RaQualia and Lilly to extend research term of ion channel collaboration

Cempra begins global phase III trial in CABP

Amgen's AMG-319 tested against lymphoma cells

Preclinical evidence of a novel dual-acting therapy for diabetes and obesity in nonhuman primates

PDE inhibitor evaluated in patients with BMD

Boosting ASO-mediated exon-skipping for the treatment of DMD

New serotonin 5-HT7 receptor ligands designed by Italian scientists

PharmaMar recommended to continue ADMYRE trial

Biogen Idec forms research consortium to develop new ALS treatments

Medivir reports topline results from phase III simeprevir trials

New tyrosine kinase inhibitors patented

The Medicines Company's pivotal SOLO-1 trial meets all endpoints

Sitavig approved in eight European countries for recurrent labial herpes

Bayer designs novel TTK protein kinase inhibitors

Swiss university presents new bombesin receptor ligands

Novel compounds for IBS patented

Merck Serono obtains additional indication approval for Erbitux in Japan

Tredaptive study fails to achieve primary endpoint

Development of a novel animal model for MLL-rearranged leukemia

Bayer files additional Japanese application for regorafenib in GIST

FDA approves Biotest's IVIG for primary humoral immunodeficiency

Pergamum's phase II trial of DPK-060 in outer ear infections meets endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...